35Pharma Secures Series C Funding to Develop Activin Inhibitors for Pulmonary Hypertension and Cardiometabolic Conditions

35Pharma, a company in the clinical stage of biopharmaceutical development, has announced the successful closing of an oversubscribed Series C financing round, raising $53 million. The funds will be used to advance the company's therapeutic pipeline, particularly focusing on Activin and GDF inhibitors. Key projects include HS135 for pulmonary hypertension and HS235 for cardiometabolic disease and obesity.

The Series C financing was led by Frazier Life Sciences, with participation from new investors such as Vivo Capital, Janus Henderson Investors, Deep Track Capital, Paradigm BioCapital Advisors, and Columbia Threadneedle. Existing investors like VenBio, Surveyor Capital, Logos Capital, and Marshall Wace also contributed.

Ilia A. Tikhomirov, CEO of 35Pharma, expressed excitement about the financing round, highlighting the addition of notable healthcare investors to their cap table. He mentioned that the funds would be used to support initial clinical proof-of-concept studies for HS135 in pulmonary hypertension and to advance HS235 through a Phase 1 trial for obesity and heart failure.

Kevin Li, M.D., Principal at Frazier Life Sciences, emphasized the significance of targeting Activin- and GDF-mediated signaling in treating cardiometabolic and pulmonary diseases. He praised 35Pharma's expertise in TGF-beta biology and protein engineering, noting that the company's clinical-stage assets show potential for best-in-class efficacy and safety. Frazier Life Sciences supports 35Pharma's goal of transforming the standard of care for pulmonary hypertension, obesity, and heart failure.

35Pharma specializes in developing TGF-beta superfamily ligand traps specifically for conditions like pulmonary hypertension, obesity, and cardiometabolic diseases. The company utilizes its scientific leadership in TGF-beta biology and advanced protein engineering to create innovative compounds. These compounds selectively neutralize pathological TGF-beta superfamily ligands while sparing beneficial ones.

35Pharma's approach aims to provide targeted treatments with high efficacy and safety profiles, addressing significant unmet medical needs. The company's progress in clinical trials and the recent successful financing round underscore its potential to make meaningful impacts in the biopharmaceutical field, particularly in the areas of pulmonary and cardiometabolic health.